BOC Group is Positioned in the 2017 Gartner Magic Quadrant for Enterprise Architecture Tools
BOC Group, a leading provider of Enterprise Management Solutions, announced today that it has been recognized as a Niche Player in the 2017 Gartner Magic Quadrant for Enterprise Architecture Tools* for its EA suite ADOIT. This is the first time the BOC Group participates in the Magic Quadrant.
“Our placement in the Niche Players segment as furthest for completeness of vision is a great achievement for us as a new entrant.”, Christoph Moser, ADOIT Product Manager says. “We are on a good track with our cloud and web-based strategy and our focus on addressing real-life challenges of EA and non-EA stakeholders. We were first to provide 100% online 30-Day Free Trials for BPM and EA suites and continue to invest in providing a unique offering for supporting various business use cases in operational tasks and transformation projects.”
With ADOIT, customers keep their businesses on track, gain insights to understand dependencies between company assets and successfully transform business and IT. This makes ADOIT an invaluable asset, especially in times of digitalization.
The latest release, ADOIT 7.6, is available online and free-of-charge for a 30-Day Free Trial of ADOIT.
For those interested in a free online presentation, please contact your regional support team.
About the Magic Quadrant
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About the BOC Group
BOC Group develops software products and services for effective and extensive Business Management in an era of digital transformation. The strengths lie in improving Enterprise Architecture and Business Process Management capabilities and facilitating better Governance, Risk and Compliance to assure audit-readiness.
ADOIT global customers include, among others, Allianz, Marel, PostFinance, Raiffeisen Bank and Vienna International Airport.
* Gartner “Magic Quadrant for Enterprise Architecture Tools” by 24 May 2017: https://www.gartner.com/lite/document/3723436.
BOC Information Technologies Consulting GmbH
Ing. Enrique Lobo Cruz
Market Development Manager
+43 1 905 10 81 2250
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Inteva Products Receives Top Innovation Award for Revolutionary Stitching Process18.6.2018 16:31 | Tiedote
Inteva Products, LLC, a leading global Tier One automotive supplier of engineered components and systems, received the top prize in the 2018 Innovation Awards presented by the European Association of Automotive Suppliers (CLEPA) at The Hague, Netherlands, on June 13. Inteva was recognized for its new real-time scanning process for the robotic stitching of automotive interiors. This innovative technology will be used on instrument panels for the 2019 Chevrolet Silverado and GMC Sierra pickup trucks. The new process enables “live” scanning and immediate adjustments to the program path of robotic stitching equipment as a component is being stitched. This approach aligns leading-edge advances in the use of lasers in automotive manufacturing with Inteva’s unique robotic stitching technologies. The advancement reduces the average cycle time of a stitched surface by approximately 20-30%. The 2018 CLEPA Innovation Awards, organized in cooperation with Deloitte, celebrate automotive excellence
P&G Advances Systemic Change for Gender Equality in Advertising at 2018 Cannes Lions Festival of Creativity18.6.2018 15:25 | Tiedote
The Procter & Gamble Company (NYSE: PG) today advanced its commitment to gender equality through a series of new actions, commitments and partnerships to increase diversity throughout the creative supply chain, leading to more accurate and positive portrayals of women in advertising and media, and driving growth and social good. Women and girls are inaccurately or negatively portrayed in 29 percent of ads and media programs*, and women continue to be underrepresented behind the camera: only 32 percent of Chief Marketing Officers, 33 percent of Chief Creative Officers and a mere 10 percent of Commercial Directors are women. These issues persist despite evidence that gender-equal ads perform 10 percent higher in trust and 26 percent higher in sales growth*. To address these issues, P&G has called for an aspiration to achieve 100% accurate and positive portrayals of women in advertising and media, supported by equal representation of women and men in the creative supply chain. P&G is lead
Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive Keratoconus18.6.2018 15:00 | Tiedote
Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has begun enrolling patients in a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on (epi-on) corneal collagen cross-linking procedure to treat patients with progressive keratoconus. Keratoconus is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens and is the leading cause of penetrating keratoplasty (corneal transplant) in the United States1. The Phase 3 clinical trial, ACP-KXL-308, is a multicenter, randomized, controlled study of a novel corneal cross-linking procedure of 275 patients with progressive keratoconus across approximately 20 sites in the United States. As is typical for U.S. Food and Drug Administration (FDA) drug trials, investigational treatments are provided at no cost to participating patients. “As a practitioner who has treated many p
Norsk Titanium Marks Milestone in U.S. Production18.6.2018 15:00 | Tiedote
Norsk Titanium (NTi), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, announced today a major milestone in qualified production. NTi’s Plattsburgh, New York Development and Qualification Center (PDQC) site was officially added to Boeing’s Qualified Producers List (QPL) on May 1 and initiated qualified production on May 15 by manufacturing its first part under the Boeing contract. This milestone is a culmination of recent company successes including certification under AS9100D and the October 2017 dedication of PDQC by New York Governor Andrew Cuomo. “We could not be prouder of our Plattsburgh, New York production operations as they put another stake in the ground for the continued success of Norsk Titanium and the state of New York,” said NTi’s Chief Operating Officer Tamara Morytko. “Receiving this qualification from Boeing, now qualifying two NTi sites for production across the globe, is a true vote of confidence in o
LG Chem Hosts Global Innovation Contest 2018 (GIC 2018)"Finding Innovations to Change the World"18.6.2018 14:00 | Tiedote
LG Chem (KRX: 051910) is exploring innovative technologies that will change the world. LG Chem announced that it would hold a Global Innovation Contest (GIC) for leading universities and research institutions around the world. This is the first time that a Korean chemical company is conducting technology contests for the entire world. From June 18th to September 30th, 2018, LG Chem will accept innovative technology ideas in five promising business areas: Energy, Environment, Functional materials, Bio technology and Platform technology. Global scholars and researchers who are interested in developing the next generation’s innovative technology and industry-academia collaboration research are welcomed to participate and submit the technical proposal through the official website (www.rnd.lgchem.com/global/gic). LG Chem will select internal experts and selection committees to evaluate the proposals considering technology innovation, marketability, and price competitiveness. Selected assign
Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)18.6.2018 14:00 | Tiedote
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. Reimbursement is effective from July 1. The innovative, long-term access agreement also provides a framework for the assessment and access of our future CF medicines. “We are delighted that people with CF in Sweden will join the thousands of others around the world who are already benefitting from our CF medicines,” said Simon Bedson, International General Manager at Vertex. “We commend the Swedish authorities for partnering with us on an innovative, long-term access agreement. In countries where Vertex remains actively involved in reimbursement discussions, we encourage these health authorities and governments to match the commitment
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme